Abstract
During cardiac pulmonary bypass (CPB), myocardial ischemia–reperfusion (I/R) induces heart glucose metabolism impairment. Our previous research showed that the decreased glucose utilization is due to decreased glucose transporter-4 (Glut-4) expression and translocation to myocyte surface membranes. This study further examined whether rosiglitazone, a synthetic agonist of peroxisome proliferator-activated receptor γ, could intervene glucose metabolism by regulating Glut-4 mRNA during I/R in dogs. Cardiac ischemia was induced by cardiopulmonary bypass for 30 or 120 min. Plasma insulin and glucose concentrations were measured at pre-bypass (control), aortic cross-clamp off (I/R) at 15, 45, and 75 min. The left ventricle biopsies were taken for the expression of Glut-4 mRNA by real-time RT-PCR. In dogs receiving 120 min ischemia, coronary arterial, venous glucose concentrations, plasma insulin levels, and insulin resistant index (IRI) were increased, but the expression of Glut-4 mRNA was decreased obviously at 15 min of reperfusion, and recovered gradually. On the other hand, these changes were relatively mild in dogs treated with rosiglitazone in cardioplegic solution and expression of Glut-4 mRNA was increased remarkably. It is concluded that the decrease in total amount of Glut-4 mRNA expression could be one of the important molecular mechanisms, which causes the myocardium insulin resistance. The longer the ischemia period, the decrease in amount of Glut-4 mRNA was more dramatic. Adding rosiglitazone into the cardioplegic solution during I/R can increase the amount of Glut-4 mRNA expression, mitigate the myocardium insulin resistance and improve the myocardium I/R injury during CPB.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- CPB:
-
Cardiac pulmonary bypass
- Glut-4:
-
Glucose transportor-4
- I/R:
-
Ischemia–reperfusion
- IRI:
-
Insulin resistance index
- LVSP:
-
Left ventricular systolic pressure
- LVEDP:
-
Left ventricular end-diastolic pressure
- PPAR-γ:
-
Peroxidase proliferation activated receptor gamma
- RT-PCR:
-
Reverse transcription-polymerase chain reaction
- TZDs:
-
Thiazolidines
References
Adachi H, Ohno T, Oguri M et al (2007) Effect of insulin sensitivity on severity of heart failure. Diabetes Res Clin Pract 77:S258–S262
Manabu I, Amira K (2005) Minireview: recent developments in the regulation of glucose transporter-4 traffic: new signals, locations, and partners. Endocrinology 146:5071–5078
Liang GY, Cai QY et al (2008) Cardiac glucose uptake and suppressed expression/translocation of myocardium glucose transport-4 in dogs undergoing ischemia-reperfusion. Exp Biol Med 233:1142–1148
Kuboki S, Shin T (2008) Peroxisome proliferator-activated receptor-gamma protects against hepatic ischemia/reperfusion injury in mice. Hepatology 47(1):215–224
Akahori T, Sho M (2007) Importance of peroxisome proliferator-activated receptor-gamma in hepatic ischemia/reperfusion injury in mice. Hepatology 47(6):784–792
Tao L, Wang Y, Gao E et al (2010) Adiponectin: an indispensable molecule in rosiglitazone cardioprotection following myocardial infarction. Circ Res 106:409–417
Matthews DR, Hosker JP, Rudenski AS (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentration in man. Diabetologia 28(7):412–419
Tl Yue, Chen JM, Bao WM (2001) In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. Circulation 104:2588–2594
Yue TL, Bao W (2005) Rosiglitazone treatment in Zucker diabetic fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Diabetes 54:554–562
Gonon AT, Bulhak A, Labruto F et al (2007) Cardioprotection mediated by rosiglitazone, a peroxisome proliferator activated receptor gamma ligand, in relation to nitric oxide. Basic Res Cardiol 102:80–89
Kilter H, Werner M (2009) The PPAR-gamma agonist rosiglitazone facilitates Akt rephosphorylation and inhibits apoptosis in cardiomyocytes during hypoxia/reoxygenation. Diabet Obes Metab 11(11):1060–1067
Zinn A, Felson S, Fisher E et al (2008) Reassessing the cardiovascular risks and benefits of thiazolidinediones. Clin Cardiol 31:397–403
Aquilante CL, Kosmiski LA, Zineh I et al (2010) Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome. Pharmacotherapy 30:236–247
Samaha FF, Szapary PO, Iqbal N et al (2006) Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 26:624–630
Morrison A, Yan X, Tong C et al (2011) Acute rosiglitazone treatment is cardioprotective against ischemia-reperfusion injury by modulating AMPK, Akt, and JNK signaling in nondiabetic mice. Am J Physiol Heart Circ Physiol 301:H895–H902
Acknowledgments
This study was supported by Guizhou Province Research Key Task Plan Science and Technology (No: 2007–1032); Guizhou Science Foundation for Excellent Scholars (No: TZJF-2008-61); Governor’s funds for Excellent Sci and Tech Teacher of Guizhou (2009-45#) and The National Nature Science Foundation of China (No: 30960382-2009).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Liu, B., Liang, G., Xu, G. et al. Intervention of rosiglitazone on myocardium Glut-4 mRNA expression during ischemia–reperfusion injury in cardio-pulmonary bypass in dogs. Mol Cell Biochem 373, 279–284 (2013). https://doi.org/10.1007/s11010-012-1501-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11010-012-1501-x